Advanced Catheter Therapies Awarded Patent

CHATTANOOGA, TN--(Marketwire - Jan 10, 2012) - Advanced Catheter Therapies, Inc. (ACT), (www.acatheter.com) today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 8088103 for its catheter technology. The company recently announced a name change from Atlanta Catheter Therapies.

The patent, entitled "Occlusion Perfusion Catheter," was issued on January 3, 2012. The Occlusion Perfusion Catheter ™ (OPC™) is a multi‐lumen balloon catheter designed to temporarily occlude a specific region from blood flow to allow the local delivery of therapeutic agents to the peripheral and coronary vasculature. Also in the company's development pipeline are devices to improve endovascular debulking procedures (the clearing of blocked blood vessels).

"The news that we've received a patent, which is part of our family of intellectual property, is just tremendous," said Paul J. Fitzpatrick, CEO of ACT. "Plus, we still have a method patent application pending, as well as continuations of our newly granted utility patent on the OPC.

"We have been very pleased during the past few months to see years of work come to fruition," Fitzpatrick added. "The initial findings from pre-clinical studies on the OPC are favorable, and we anticipate filing a 510(k) application with the U.S. FDA by the end of Q1, 2012."

Advanced Catheter Therapies recently raised a total of $2.98 million in Series A equity financing through an investment consortium in Chattanooga, TN. ACT operates as a highly efficient research and development organization, developing its product line through a phased approach. The company's role in product development includes design, IP patent filing, engineering, working prototyping, testing and regulatory approvals. Once the device is ready for human trials and/or manufacturing, sales and distribution, ACT will out-license or sell each device technology to a strategic partner.

About ACT
Advanced Catheter Therapies, an early stage research and development medical device company, has a portfolio of innovative catheter technologies targeting vascular disease including thrombosis, inflammation, occlusions and restenosis. ACT was founded in 2008 by Dr. Rex Teeslink, M.D., an interventional radiologist, Dirk Hoyns, a medical device engineer, and the Medical Device Development Group (MDDG). Paul J. Fitzpatrick joined the team as CEO in January 2009 and Kevin Dye became vice president of finance and operations in 2010.